CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer

Paul D.P. Pharoah; Carla Oliveira; José Carlos Machado; Gisella Keller; Holger Vogelsang; Holger Laux; Karl Friedrich Becker; Heidi Hahn; Suzanne M. Paproski; Lindsay A. Brown; Carlos Caldas; David Huntsman

doi:10.1002/ijc.10590

CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer

Paul D.P. Pharoah, Carla Oliveira, José Carlos Machado, Gisella Keller, Holger Vogelsang, Holger Laux, Karl Friedrich Becker, Heidi Hahn, Suzanne M. Paproski, Lindsay A. Brown, Carlos Caldas, David Huntsman

Default

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

We have combined data from case control studies designed to test the hypothesis that the c-160a promotor polymorphism in the gene coding for the cell adhesion molecule E-cadherin (CDH 1) is associated with stomach cancer. A total of 899 individuals (433 patients and 466 controls) were analyzed. The genotype frequencies did not differ significantly between cases and controls, and the genotype-specific risks were not significantly different from unity, with an odds ratio for heterozygotes compared with the common homozygote of 1.3 (95% CI 0.98-1.8) and 1.2 (0.68-2.0) for rare homozygotes compared with common homozygotes. We found no evidence for differences in risk for the intestinal- and diffusetype histopathologic subgroups.

Original language	English
Pages (from-to)	196-197
Number of pages	2
Journal	International Journal of Cancer
Volume	101
Issue number	2
DOIs	https://doi.org/10.1002/ijc.10590
State	Published - 10 Sep 2002

Keywords

CDH1
Polymorphism
Stomach cancer
Susceptibility

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ijc.10590

Cite this

@article{7b720e3b509a4f83a5caef0d4d51f6cb,

title = "CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer",

abstract = "We have combined data from case control studies designed to test the hypothesis that the c-160a promotor polymorphism in the gene coding for the cell adhesion molecule E-cadherin (CDH 1) is associated with stomach cancer. A total of 899 individuals (433 patients and 466 controls) were analyzed. The genotype frequencies did not differ significantly between cases and controls, and the genotype-specific risks were not significantly different from unity, with an odds ratio for heterozygotes compared with the common homozygote of 1.3 (95% CI 0.98-1.8) and 1.2 (0.68-2.0) for rare homozygotes compared with common homozygotes. We found no evidence for differences in risk for the intestinal- and diffusetype histopathologic subgroups.",

keywords = "CDH1, Polymorphism, Stomach cancer, Susceptibility",

author = "Pharoah, {Paul D.P.} and Carla Oliveira and Machado, {Jos{\'e} Carlos} and Gisella Keller and Holger Vogelsang and Holger Laux and Becker, {Karl Friedrich} and Heidi Hahn and Paproski, {Suzanne M.} and Brown, {Lindsay A.} and Carlos Caldas and David Huntsman",

year = "2002",

month = sep,

day = "10",

doi = "10.1002/ijc.10590",

language = "English",

volume = "101",

pages = "196--197",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer

AU - Pharoah, Paul D.P.

AU - Oliveira, Carla

AU - Machado, José Carlos

AU - Keller, Gisella

AU - Vogelsang, Holger

AU - Laux, Holger

AU - Becker, Karl Friedrich

AU - Hahn, Heidi

AU - Paproski, Suzanne M.

AU - Brown, Lindsay A.

AU - Caldas, Carlos

AU - Huntsman, David

PY - 2002/9/10

Y1 - 2002/9/10

N2 - We have combined data from case control studies designed to test the hypothesis that the c-160a promotor polymorphism in the gene coding for the cell adhesion molecule E-cadherin (CDH 1) is associated with stomach cancer. A total of 899 individuals (433 patients and 466 controls) were analyzed. The genotype frequencies did not differ significantly between cases and controls, and the genotype-specific risks were not significantly different from unity, with an odds ratio for heterozygotes compared with the common homozygote of 1.3 (95% CI 0.98-1.8) and 1.2 (0.68-2.0) for rare homozygotes compared with common homozygotes. We found no evidence for differences in risk for the intestinal- and diffusetype histopathologic subgroups.

AB - We have combined data from case control studies designed to test the hypothesis that the c-160a promotor polymorphism in the gene coding for the cell adhesion molecule E-cadherin (CDH 1) is associated with stomach cancer. A total of 899 individuals (433 patients and 466 controls) were analyzed. The genotype frequencies did not differ significantly between cases and controls, and the genotype-specific risks were not significantly different from unity, with an odds ratio for heterozygotes compared with the common homozygote of 1.3 (95% CI 0.98-1.8) and 1.2 (0.68-2.0) for rare homozygotes compared with common homozygotes. We found no evidence for differences in risk for the intestinal- and diffusetype histopathologic subgroups.

KW - CDH1

KW - Polymorphism

KW - Stomach cancer

KW - Susceptibility

UR - http://www.scopus.com/inward/record.url?scp=0037056235&partnerID=8YFLogxK

U2 - 10.1002/ijc.10590

DO - 10.1002/ijc.10590

M3 - Article

C2 - 12209998

AN - SCOPUS:0037056235

SN - 0020-7136

VL - 101

SP - 196

EP - 197

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - 2

ER -

CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this